These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 15690687

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Resistance trends in Haemophilus influenzae (PROTEKT years 1-3 [1999-20021).
    Low DE.
    J Chemother; 2004 Dec; 16 Suppl 6():49-61. PubMed ID: 15690685
    [No Abstract] [Full Text] [Related]

  • 3. Introduction to PROTEkT: years 1-3 (1999-2002).
    Harding I.
    J Chemother; 2004 Dec; 16 Suppl 6():5-7. PubMed ID: 15690681
    [No Abstract] [Full Text] [Related]

  • 4. PROTEKT years 1-3 (1999-2002): study design and methodology.
    Harding I, Felmingham D.
    J Chemother; 2004 Dec; 16 Suppl 6():9-18. PubMed ID: 15690682
    [No Abstract] [Full Text] [Related]

  • 5. Resistance trends in Moraxella catarrhalis (PROTEKT years 1-3 [1999-2002]).
    Canton R.
    J Chemother; 2004 Dec; 16 Suppl 6():63-70. PubMed ID: 15690686
    [No Abstract] [Full Text] [Related]

  • 6. Global surveillance through PROTEKT: the first year.
    Grüneberg RN.
    J Chemother; 2002 Jul; 14 Suppl 3():9-16. PubMed ID: 12418556
    [Abstract] [Full Text] [Related]

  • 7. Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Germany and activity of the Ketolide Telithromycin: results from the PROTEKT surveillance study (1999-2000).
    Reinert RR, Rodloff AC, Halle E, Baer W, Beyreiss B, Seifert H, Wichelhaus TA, Maass M, Mehl M.
    Chemotherapy; 2004 Jun; 50(3):143-51. PubMed ID: 15272227
    [Abstract] [Full Text] [Related]

  • 8. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin.
    Felmingham D.
    J Infect; 2002 Feb; 44 Suppl A():3-10. PubMed ID: 12150493
    [Abstract] [Full Text] [Related]

  • 9. Introduction: PROTEKT against respiratory tract infection.
    Stratton CW.
    J Chemother; 2002 Jul; 14 Suppl 3():5-8. PubMed ID: 12418555
    [No Abstract] [Full Text] [Related]

  • 10. What can PROTEKT tell us at a local level?
    Inoue M.
    J Chemother; 2002 Jul; 14 Suppl 3():17-24. PubMed ID: 12418557
    [Abstract] [Full Text] [Related]

  • 11. Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against community-acquired bacterial respiratory tract pathogens in the United States: findings from the PROTEKT US study, 2000-2001.
    Stratton CW, Brown SD.
    Clin Ther; 2004 Apr; 26(4):522-30. PubMed ID: 15189749
    [Abstract] [Full Text] [Related]

  • 12. Resistance trends in Streptococcus pneumoniae (PROTEKT years 1-3 [1999-2002]).
    Schito GC.
    J Chemother; 2004 Dec; 16 Suppl 6():19-33. PubMed ID: 15690683
    [No Abstract] [Full Text] [Related]

  • 13. Resistance phenotypes and multi-drug resistance in Streptococcus pneumoniae (PROTEKT years 1-3 [1999-20021).
    Reinert RR.
    J Chemother; 2004 Dec; 16 Suppl 6():35-48. PubMed ID: 15690684
    [No Abstract] [Full Text] [Related]

  • 14. [In vitro activity of telithromycin against community acquired respiratory pathogens].
    Ulloa F MT, Camponovo C R, Fernández V A, García C P, Prado J V, González A P, Rojas S P, Inostroza S J, Lafourcade R M, Aguilera A L, Porte T L, Cruz P C, Joyas M A, Alcaide L B, Pinto C ME, Giglio M MS.
    Rev Med Chil; 2005 Apr; 133(4):419-25. PubMed ID: 15953948
    [Abstract] [Full Text] [Related]

  • 15. Prevalence of macrolide and tetracycline resistance mechanisms in Streptococcus pyogenes isolates and in vitro susceptibility to telithromycin.
    Betriu C, Culebras E, Redondo M, Rodríguez-Avial I, Gómez M, Boloix A, Picazo JJ.
    J Antimicrob Chemother; 2002 Sep; 50(3):436-8. PubMed ID: 12205076
    [No Abstract] [Full Text] [Related]

  • 16. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01.
    Doern GV, Brown SD.
    J Infect; 2004 Jan; 48(1):56-65. PubMed ID: 14667792
    [Abstract] [Full Text] [Related]

  • 17. Resistance trends in Staphylococcus aureus (PROTEKT years 1-3 [1999-2002]).
    Jenkins SG.
    J Chemother; 2004 Dec; 16 Suppl 6():83-91. PubMed ID: 15690688
    [No Abstract] [Full Text] [Related]

  • 18. Prevalence and characterization of macrolide resistance in clinical isolates of Streptococcus pneumoniae and Streptococcus pyogenes from North America.
    Hoban DJ.
    J Chemother; 2002 Jul; 14 Suppl 3():25-30. PubMed ID: 12418558
    [Abstract] [Full Text] [Related]

  • 19. Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Latin America: results from the PROTEKT surveillance study (1999-2000).
    Mendes C, Marin ME, Quiñones F, Sifuentes-Osornio J, Siller CC, Castanheira M, Zoccoli CM, López H, Súcari A, Rossi F, Angulo GB, Segura AJ, Starling C, Mimica I, Felmingham D.
    Braz J Infect Dis; 2003 Feb; 7(1):44-61. PubMed ID: 12807691
    [Abstract] [Full Text] [Related]

  • 20. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999-2000: findings of the PROTEKT surveillance study.
    Hoban D, Waites K, Felmingham D.
    Diagn Microbiol Infect Dis; 2003 Apr; 45(4):251-9. PubMed ID: 12729995
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.